Lyell Immunopharma, Inc.
A clinical-stage company developing CAR T-cell therapies for cancer.
LYEL | US
Overview
Corporate Details
- ISIN(s):
- US55083R1041
- LEI:
- Country:
- United States of America
- Address:
- 201 HASKINS WAY, 94080 SOUTH SAN FRANCISCO
- Website:
- https://lyell.com/
- Sector:
- Manufacturing
Description
Lyell Immunopharma, Inc. is a clinical-stage cell therapy company that develops Chimeric Antigen Receptor (CAR) T-cell therapies for cancer. The company pioneers T-cell reprogramming technologies designed to overcome the primary barriers to durable clinical responses in patients. Its scientific approach focuses on enhancing T-cell function and fitness to improve the efficacy and persistence of its therapeutic candidates. Lyell's pipeline targets both solid tumors and hematologic malignancies, addressing significant unmet medical needs in oncology.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Lyell Immunopharma, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Lyell Immunopharma, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Lyell Immunopharma, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
